Birdwatch Note
2024-03-09 14:02:42 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
La cafeína es un vasoconstrictor y su consumo con fines medicinales puede tener efectos adversos. Si bien puede aliviar los dolores de cabeza, puede ser problemática para personas que sufren hipertensión, por lo que no se debe hacer creer que es un vasodilatador. https://www.elsevier.es/es-revista-neurologia-295-articulo-cafeina-cefalea-consideraciones-especiales-S0213485315000158#:~:text=La%20cafe%C3%ADna%20es%20entonces%20un,la%20absorci%C3%B3n%20de%20otros%20analg%C3%A9sicos.
Written by 0293F836FCFB3AD041FBFAA607539FA0160719031F13B6FEE3555BFFCDA7AF5E
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1766380661747622030
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1766464631277580662
- noteId - 1766464631277580662
- participantId -
- noteAuthorParticipantId - 0293F836FCFB3AD041FBFAA607539FA0160719031F13B6FEE3555BFFCDA7AF5E Participant Details
- createdAtMillis - 1709992962079
- tweetId - 1766380661747622030
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- La cafeína es un vasoconstrictor y su consumo con fines medicinales puede tener efectos adversos. Si bien puede aliviar los dolores de cabeza, puede ser problemática para personas que sufren hipertensión, por lo que no se debe hacer creer que es un vasodilatador. https://www.elsevier.es/es-revista-neurologia-295-articulo-cafeina-cefalea-consideraciones-especiales-S0213485315000158#:~:text=La%20cafe%C3%ADna%20es%20entonces%20un,la%20absorci%C3%B3n%20de%20otros%20analg%C3%A9sicos.
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-03-09 14:02:42 UTC (1709992962079) |
2024-03-09 16:53:22 UTC (1710003202402) |
CURRENTLY_RATED_HELPFUL | 2024-03-10 02:46:15 UTC (1710038775311) |
CURRENTLY_RATED_HELPFUL | 2024-03-09 16:53:22 UTC (1710003202402) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-03-09 18:59:59 -0600 | Rating Details | |
| 2024-03-09 17:09:50 -0600 | Rating Details | |
| 2024-03-09 16:44:24 -0600 | Rating Details | |
| 2024-03-09 13:54:10 -0600 | Rating Details | |
| 2024-03-09 13:34:43 -0600 | Rating Details | |
| 2024-03-09 13:19:13 -0600 | Rating Details | |
| 2024-03-09 13:04:47 -0600 | Rating Details | |
| 2024-03-09 13:04:34 -0600 | Rating Details | |
| 2024-03-09 12:59:16 -0600 | Rating Details | |
| 2024-03-09 12:59:08 -0600 | Rating Details | |
| 2024-03-09 12:02:04 -0600 | Rating Details | |
| 2024-03-09 12:01:31 -0600 | Rating Details | |
| 2024-03-09 11:20:33 -0600 | Rating Details | |
| 2024-03-09 11:10:25 -0600 | Rating Details | |
| 2024-03-09 10:36:30 -0600 | Rating Details | |
| 2024-03-09 10:13:42 -0600 | Rating Details | |
| 2024-03-09 10:13:17 -0600 | Rating Details | |
| 2024-03-09 10:08:40 -0600 | Rating Details | |
| 2024-03-09 10:08:16 -0600 | Rating Details | |
| 2024-03-09 09:33:44 -0600 | Rating Details | |
| 2024-03-09 08:46:48 -0600 | Rating Details | |
| 2024-03-09 08:32:07 -0600 | Rating Details | |
| 2024-03-09 08:25:02 -0600 | Rating Details | |
| 2024-03-10 16:16:54 -0500 | Rating Details | |
| 2024-03-10 09:13:03 -0500 | Rating Details | |
| 2024-03-10 03:37:24 -0500 | Rating Details | |
| 2024-03-10 00:37:31 -0600 | Rating Details | |
| 2024-03-09 23:09:51 -0600 | Rating Details | |
| 2024-03-09 21:14:54 -0600 | Rating Details | |
| 2024-03-09 19:45:35 -0600 | Rating Details | |
| 2024-03-09 19:19:33 -0600 | Rating Details | |
| 2024-03-09 14:20:30 -0600 | Rating Details | |
| 2024-03-09 12:29:48 -0600 | Rating Details | |
| 2024-03-09 11:13:48 -0600 | Rating Details | |
| 2024-03-09 11:13:12 -0600 | Rating Details | |
| 2024-03-09 10:48:10 -0600 | Rating Details | |
| 2024-03-09 10:41:18 -0600 | Rating Details | |
| 2024-03-09 10:23:59 -0600 | Rating Details | |
| 2024-03-09 10:00:21 -0600 | Rating Details | |
| 2024-03-09 09:54:05 -0600 | Rating Details | |
| 2024-03-09 09:48:20 -0600 | Rating Details | |
| 2024-03-09 09:19:02 -0600 | Rating Details | |
| 2024-03-09 08:55:51 -0600 | Rating Details | |
| 2024-03-09 08:36:56 -0600 | Rating Details | |
| 2024-03-09 08:33:35 -0600 | Rating Details | |
| 2024-03-09 08:11:51 -0600 | Rating Details | |
| 2024-03-10 05:13:42 -0500 | Rating Details | |
| 2024-03-10 05:11:58 -0500 | Rating Details | |
| 2024-03-09 21:25:21 -0600 | Rating Details | |
| 2024-03-09 19:49:26 -0600 | Rating Details | |
| 2024-03-09 19:39:05 -0600 | Rating Details | |
| 2024-03-09 18:25:06 -0600 | Rating Details | |
| 2024-03-09 17:46:46 -0600 | Rating Details | |
| 2024-03-09 14:12:55 -0600 | Rating Details | |
| 2024-03-09 14:05:19 -0600 | Rating Details | |
| 2024-03-09 13:11:44 -0600 | Rating Details | |
| 2024-03-09 13:09:18 -0600 | Rating Details | |
| 2024-03-09 11:00:29 -0600 | Rating Details | |
| 2024-03-09 10:44:51 -0600 | Rating Details | |
| 2024-03-09 10:44:22 -0600 | Rating Details | |
| 2024-03-09 10:30:37 -0600 | Rating Details | |
| 2024-03-09 10:04:44 -0600 | Rating Details | |
| 2024-03-09 10:02:09 -0600 | Rating Details | |
| 2024-03-09 09:39:46 -0600 | Rating Details | |
| 2024-03-09 09:20:39 -0600 | Rating Details | |
| 2024-03-09 09:02:06 -0600 | Rating Details | |
| 2024-03-09 08:26:45 -0600 | Rating Details | |
| 2024-03-13 09:27:41 -0500 | Rating Details | |
| 2024-03-13 14:52:59 -0500 | Rating Details | |
| 2024-03-13 11:42:42 -0500 | Rating Details | |
| 2024-03-13 09:26:18 -0500 | Rating Details | |
| 2024-03-09 11:08:54 -0600 | Rating Details | |
| 2024-03-13 12:05:39 -0500 | Rating Details |